130 related articles for article (PubMed ID: 7955749)
1. Adjuvant intraperitoneal chromic phosphate therapy in a woman with early ovarian carcinoma and pelvic infection with resulting catastrophic complications.
McGowan L
Clin Nucl Med; 1994 Aug; 19(8):696-8. PubMed ID: 7955749
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal chromic phosphate in ovarian cancer: risks and benefits.
Potter ME; Partridge EE; Shingleton HM; Soong SJ; Kim RY; Hatch KD; Austin JM
Gynecol Oncol; 1989 Mar; 32(3):314-8. PubMed ID: 2920951
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal radioactive chromic phosphate P 32 in the treatment of ovarian cancer.
Powell JL; Burrell MO; Kirchner AB
South Med J; 1987 Dec; 80(12):1513-7. PubMed ID: 3423895
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging.
Soper JT; Berchuck A; Clarke-Pearson DL
Cancer; 1991 Aug; 68(4):725-9. PubMed ID: 1855171
[TBL] [Abstract][Full Text] [Related]
5. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma.
Soper JT; Creasman WT; Clarke-Pearson DL; Sullivan DC; Vergadoro F; Johnston WW
Am J Obstet Gynecol; 1985 Sep; 153(2):191-6. PubMed ID: 4037013
[TBL] [Abstract][Full Text] [Related]
6. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.
Klaassen D; Shelley W; Starreveld A; Kirk M; Boyes D; Gerulath A; Levitt M; Fraser R; Carmichael J; Methot Y
J Clin Oncol; 1988 Aug; 6(8):1254-63. PubMed ID: 3045264
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging.
Soper JT; Wilkinson RH; Bandy LC; Clarke-Pearson DL; Creasman WT
Am J Obstet Gynecol; 1987 May; 156(5):1153-8. PubMed ID: 3578429
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary.
Peters WA; Smith MR; Cain JM; Lee RB; Yon JL
Gynecol Oncol; 1992 Nov; 47(2):146-9. PubMed ID: 1468691
[TBL] [Abstract][Full Text] [Related]
9. Pleuroperitoneal migration of intraperitoneal phosphorus-32-chromic phosphate therapy for stage I ovarian carcinoma.
Wilkinson RH
J Nucl Med; 1996 Apr; 37(4):636-9. PubMed ID: 8691256
[TBL] [Abstract][Full Text] [Related]
10. Ovarian carcinoma: adjuvant treatment with P-32.
Reddy S; Sutton GP; Stehman FB; Hornback NB; Ehrlich CE
Radiology; 1987 Oct; 165(1):275-8. PubMed ID: 3628782
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal radioactive chromic phosphate (P32) in the treatment of ovarian cancer.
Powell JL; Kirchner AB
J Med Assoc Ga; 1984 Jan; 73(1):21-5. PubMed ID: 6707541
[No Abstract] [Full Text] [Related]
13. Intraperitoneal distribution imaging prior to chromic phosphate (P-32) therapy in ovarian cancer patients.
Tulchinsky M; Eggli DF
Clin Nucl Med; 1994 Jan; 19(1):43-8. PubMed ID: 8137583
[TBL] [Abstract][Full Text] [Related]
14. Phosphorus-32-chromic phosphate for ovarian cancer: I. Fractionated low-dose intraperitoneal treatments in conjunction with platinum analog chemotherapy.
Pattillo RA; Collier BD; Abdel-Dayem H; Ozker K; Wilson C; Ruckert AC; Hamilton K
J Nucl Med; 1995 Jan; 36(1):29-36. PubMed ID: 7799078
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging.
Soper JT; Berchuck A; Dodge R; Clarke-Pearson DL
Obstet Gynecol; 1992 Jun; 79(6):993-7. PubMed ID: 1579329
[TBL] [Abstract][Full Text] [Related]
16. Update on the role of radiotherapy in ovarian cancer.
Lanciano R; Reddy S; Corn B; Randall M
Semin Oncol; 1998 Jun; 25(3):361-71. PubMed ID: 9633849
[No Abstract] [Full Text] [Related]
17. Radioactivity in blood and urine following intraperitoneal instillation of chromic phosphate in patients with and without ascites.
Bakri YN; Given FT
Am J Obstet Gynecol; 1984 Sep; 150(2):184-8. PubMed ID: 6476040
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal radioactive phosphate in early ovarian carcinoma: an analysis of complications.
Walton LA; Yadusky A; Rubinstein L
Int J Radiat Oncol Biol Phys; 1991 May; 20(5):939-44. PubMed ID: 2022522
[TBL] [Abstract][Full Text] [Related]
19. External beam pelvic radiotherapy plus intraperitoneal radioactive chronic phosphate in early stage ovarian cancer: a toxic combination. A National Cancer Institute of Canada Clinical Trials Group Report.
Klaassen D; Starreveld A; Shelly W; Miller A; Boyes D; Gerulath A; Levitt M
Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1801-4. PubMed ID: 4044343
[TBL] [Abstract][Full Text] [Related]
20. Five and ten year estimated survival and disease-free rates after intraperitoneal chromic phosphate; stage I ovarian adenocarcinoma.
Piver MS; Lele SB; Bakshi S; Parthasarathy KL; Emrich LJ
Am J Clin Oncol; 1988 Oct; 11(5):515-9. PubMed ID: 3177251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
